SVB Leerink: This "holy grail" of the vaccine industry could be worth $10 billion

Name: SVB Leerink: This "holy grail" of the vaccine industry could be worth $10 billion
Uploaded: 2021-06-16T10:48:48.000Z
Duration: 4 min 21 s
Description: Geoffrey Porges, SVB Leerink Director of Therapeutics Research and Senior Biotechnology Analyst, joins Worldwide Exchange to discuss his latest note on the RSV vaccine development industry.

Geoffrey Porges, SVB Leerink Director of Therapeutics Research and Senior Biotechnology Analyst, joins Worldwide Exchange to discuss his latest note on the RSV vaccine development industry.

04:21

Wed, Jun 16 20216:48 AM EDT